Fig. 2From: Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan AfricaScatter plot of max post-baseline ALT absolute value versus cipargamin AUC (area under the curve) by treatment group (Safety set)Back to article page